Refractory high grade B-cell lymphoma
Clinical trials for Refractory high grade B-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Refractory high grade B-cell lymphoma trials appear
Sign up with your email to follow new studies for Refractory high grade B-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Three-Drug cocktail aims to tackle tough lymphomas
Disease control OngoingThis study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control PausedThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC